number of access : ?
number of downloads : ?
ID 109985
Title Alternative
転移性大腸癌に対する2次治療としてのIRIS+panitumumab療法の有効性の検討
IRIS plus panitumumab for metastatic CRC
Author
Takaoka, Toshi Tokushima University
Shimoyama, Rai Shonan Kamakura General Hospital
Kawamoto, Shunji Fukuoka Tokushukai Medical Center
Sakamoto, Kazuki Kishiwada Tokushukai Hospital
Goda, Fuminori Kagawa University Hospital
Negoro, Yuji Kochi Health Sciences center
Tsuji, Akihito Kobe City Medical Center General Hospital
Yoshizaki, Koji Sapporo Higashi Tokushukai Hospital
Yano, Hiromi Tokushima University
Kimura, Masako Tokushima University
Niitsu, Yoshiro Sapporo Medical University
Keywords
colorectal cancer
IRIS
panitumumab
second-line therapy
chemotherapy
irinotecan
S-1
Content Type
Thesis or Dissertation
Description
Background Irinotecan plus S-1 (IRIS) is the only oral fluoropyrimidine-based regimen reported to be non-inferior to FOLFIRI and widely used in clinical practice for metastatic colorectal cancer (mCRC) patients. However, the combination of IRIS plus an anti-EGFR agent has not been evaluated previously. This study aimed to investigate the feasibility and efficacy of IRIS with panitumumab as second-line therapy for wild-type KRAS mCRC.
Methods Main inclusion criteria were patients with wild-type KRAS mCRC refractory to one prior chemotherapy regimen for mCRC, ECOG PS 0-2, and age ≥ 20 years. Patients received panitumumab (6mg/kg) and irinotecan (100mg/m2) on days 1 and 15 and S-1 (40-60 mg according to body surface area) twice daily for 2 weeks, repeated every 4 weeks. The primary endpoint was the feasibility of the therapy. The secondary endpoints were response rate (RR), progression-free survival (PFS), and overall survival (OS).
Results A total of 36 patients received protocol treatment in eight centers. Of these, 23 patients (63.9%) completed protocol treatment, demonstrating achievement of the primary endpoint. The most frequent grade 3/4 toxicities were diarrhea (16.7%), acne-like rash (13.9%), and neutropenia (11.1%). The overall RR was 33.3% (12/36). Of these 4 five underwent conversion surgery. Median PFS and OS were 9.5 months (95% CI 3.5-15.4 months) and 20.1 months (95% CI 16.7-23.2 months), respectively.
Conclusion IRIS plus panitumumab has an acceptable toxicity profile and a promising efficacy in patients with previously treated wild-type KRAS mCRC. Accordingly, this regimen can be an additional treatment option for second-line chemotherapy in wild-type KRAS mCRC.
Journal Title
Cancer Chemotherapy and Pharmacology
ISSN
03445704
14320843
NCID
AA00598397
AA1161885X
Publisher
Springer Berlin Heidelberg
Volume
78
Issue
2
Start Page
397
End Page
403
Published Date
2016-06-24
Remark
内容要旨・審査要旨・論文本文の公開:
内容要旨・審査要旨 : LID201701051002.pdf
論文本文 : k2997_fulltext.pdf
著者の申請により要約(2017-01-05公開)に替えて論文全文を公開(2019-04-23)
本論文は, 著者Toshi Takaokaの学位論文として提出され, 学位審査・授与の対象となっている。
Rights
The final publication is available at link.springer.com.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
ETD
MEXT report number
甲第2997号
Diploma Number
甲医第1302号
Granted Date
2016-10-27
Degree Name
Doctor of Medical Science
Grantor
Tokushima University
departments
Medical Sciences
University Hospital